The global C-reactive protein testing market size is expected to reach USD 2,331.22 million by 2032, expected to grow at a CAGR of 2.7% during the forecast period.
C-Reactive Protein (CRP) testing is a crucial diagnostic tool in healthcare, primarily used to assess inflammation in the body. Elevated CRP levels are indicative of conditions such as infections, autoimmune disorders, and cardiovascular diseases. This market, driven by the growing prevalence of chronic diseases, advancements in testing technology, and increasing awareness about inflammation-related health risks, is experiencing significant growth.
Research Scope
The research in the C-Reactive Protein testing market spans a range of important areas:
- Improved Test Sensitivity and Specificity
- Developing more sensitive CRP tests capable of detecting low-grade inflammation and improving specificity for various inflammatory diseases.
- Automation and Miniaturization of Testing Devices
- Advances in lab-on-a-chip and portable testing devices aim to provide faster, cheaper, and more efficient CRP testing.
- CRP as a Marker for Other Diseases
- Research is being conducted to explore the role of CRP as a biomarker in additional diseases, such as cancer and neurodegenerative disorders.
Download Free Sample PDF Copy of the Report:
Some of the companies working in the global CRP market include:
- Abaxis, Inc.
- Abbott, Danaher
- Aidian
- BODITECH MED, INC.
- F. Getein Biotech, Inc.
- Hoffmann-La Roche Ltd.
- HORIBA, Ltd., Inc.
- Laboratory Corporation of America Holdings
- Merck KGaA
Challenges in the Market
- High Cost of Advanced Tests
- While basic CRP testing is affordable, high-sensitivity CRP and other advanced tests can be costly, limiting their accessibility in resource-constrained regions.
- Lack of Awareness in Emerging Markets
- Despite the growing prevalence of chronic diseases, awareness and understanding of the benefits of CRP testing are still limited in many developing countries.
- Regulatory and Reimbursement Issues
- Variations in healthcare regulations and reimbursement policies across regions can affect market growth and accessibility of CRP testing, particularly in emerging markets.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
C-Reactive Protein Testing, Assay Type Outlook (Revenue – USD Million, 2019 – 2032)
- Immuno-turbidimetric Assay
- ELISA
- Clinical
- Non-clinical
- Chemiluminescence Immunoassay
- Others
C-Reactive Protein Testing, Detection Range Outlook (Revenue – USD Million, 2019 – 2032)
- hs (high sensitivity) CRP
- Conventional CRP
- cCRP
C-Reactive Protein Testing, Disease Area Outlook (Revenue – USD Million, 2019 – 2032)
- Cardiovascular Diseases
- Cancer
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Endometriosis
- Lupus
- Others
C-Reactive Protein Testing, End-Use (Revenue – USD Million, 2019 – 2032)
- Clinics
- Hospitals
- Laboratories
- Assisted Living Healthcare Facilities
- Home Care Settings
- Others
Recent Developments
- In November 2020, a study conducted by U.S. researchers supported the use of daily C-reactive protein (CRP) values in hospitalized COVID-19 patients.
- In May 2020, ProciseDx submitted a 510k application for the company CRP test. This test utilizes ProciseDx’s FRET (Fluorescent Resonance Energy Transfer) Point of Care tools, commonly used as an inflammatory marker in gastrointestinal therapy.
The C-Reactive Protein (CRP) Testing Market is poised for significant growth due to the increasing prevalence of chronic diseases, advancements in testing technologies, and growing demand for point-of-care solutions. While challenges like cost, accessibility, and regulatory hurdles remain, the market’s potential for improved diagnostic capabilities and early disease detection is vast. As the healthcare industry continues to evolve, CRP testing will play an integral role in managing inflammation-related health conditions and improving patient outcomes.